靛玉红(indirubin)系中药青黛治疗慢性粒细胞白血病的有效成分,目前已用半合成和全合成两种方法进行试制生产,并正在进一步扩大临床实验。为了控制产品质量,我们对靛玉红含量测定方法进行了研究。 文献报道的靛玉红测定方法,我们发现测定结果往往偏高。据推测在靛玉红的合成过程中,可能生成一些靛玉红的同分异构体——靛蓝和靛棕,经硅胶G薄层层析,确证这两种 Indirubin is the active ingredient of the Chinese medicine Qingjing for the treatment of chronic myelogenous leukemia. It has been currently undergoing trial production with semi-synthetic and total synthetic methods. It is further expanding clinical trials. In order to control the quality of the product, we studied the determination of indirubin content. As reported in the literature for indirubin assays, we have found that the results are often high. It is speculated that during the synthesis of indirubin, some isomers of indirubin, indigo and indigo, may be generated and confirmed by silica gel G thin layer chromatography.